. "CZ - \u010Cesk\u00E1 republika" . . . "Cutaneous malignant melanoma originates from neoplastic proliferation of melanocytes. Due to its early lymphogenic and haematogenic metastazing, melanoma belongs to the most malignant tumours. The disease occurs quite early; one quarter of patients with melanoma is younger than 40 years and the mean age of a melanoma patient is 54 years. The incidence of this tumour is growing constantly, about 4% per year. In the central Europe the current incidence is approximately 14 cases per 100.000 inhabitants per year, in the USA it represents 10 to 25 cases and the highest incidence of 50-60 new cases is reported from Australia. The patient\u00B4s prognosis depends on the tumour thickness and the early diagnostics is therefore essential for the favourable disease outcome. The accuracy of the melanoma clinical diagnostics has been enhanced by introduction of dermoscopy, particularly by its digital form. For the trained dermatologist it improves the accuracy of the clinical decision from usual 70 to more than 95%. Th"@en . "4" . . "Malign\u00ED melanom: standardy a inovace v diagnostice a terapii" . "Malign\u00ED melanom: standardy a inovace v diagnostice a terapii"@cs . "7"^^ . "[7841523A95EC]" . "Malign\u00ED melanom k\u016F\u017Ee vznik\u00E1 neoplastickou proliferac\u00ED melanocyt\u016F. Tendence k \u010Dasn\u00E9mu lymfogenn\u00EDmu a hematogenn\u00EDmu metast\u00E1zov\u00E1n\u00ED \u0159ad\u00ED melanom k vysoce zhoubn\u00FDm n\u00E1dor\u016Fm. Onemocn\u011Bn\u00ED se objevuje pom\u011Brn\u011B brzy, a tak je \u010Dtvrtina pacient\u016F s melanomem mlad\u0161\u00ED 40 let a pr\u016Fm\u011Brn\u00FD v\u011Bk melanomov\u00E9ho pacienta je 54 let. Incidence tohoto tumoru konstantn\u011B stoup\u00E1, ro\u010Dn\u011B zhruba o 5%. Ve st\u0159edn\u00ED Evrop\u011B se v sou\u010Dasnosti pohybuje incidence kolem 14 p\u0159\u00EDpad\u016F na 100 000 obyvatel za rok, v USA mezi 10-25 a nejvy\u0161\u0161\u00ED incidence 50-60 nov\u00FDch p\u0159\u00EDpad\u016F je zaznamen\u00E1v\u00E1na v Austr\u00E1lii. Progn\u00F3za pacienta je v\u00FDznamn\u011B z\u00E1visl\u00E1 na tlou\u0161\u0165ce tumoru, proto je v\u010Dasn\u00E1 diagnostika nezbytn\u00FDm p\u0159edpokladem p\u0159\u00EDzniv\u00E9ho pr\u016Fb\u011Bhu onemocn\u011Bn\u00ED. Zv\u00FD\u0161en\u00ED p\u0159esnosti klinick\u00E9 diagn\u00F3zy melanomu p\u0159inesla dermatoskopie, p\u0159edev\u0161\u00EDm pak ve sv\u00E9 digit\u00E1ln\u00ED podob\u011B, kter\u00E1 zlep\u0161\u00ED \u0161kolen\u00E9mu dermatologovi p\u0159esnost klinick\u00E9 diagn\u00F3zy ze 70 na v\u00EDce ne\u017E 95%. Mortalita na malign\u00ED melanom z\u016Fst\u00E1v\u00E1 od osmdes\u00E1t\u00FDch let 20. stolet\u00ED konstantn\u00ED, a proto je velk\u00FD tlak na objeven\u00ED nov\u00FDch l\u00E1te"@cs . "0008-7335" . "\u010Casopis l\u00E9ka\u0159\u016F \u010Desk\u00FDch" . . . . . . . . "324480" . "Vedral, Tom\u00E1\u0161" . "Malign\u00ED melanom: standardy a inovace v diagnostice a terapii" . "P(1A8243)" . . . "3"^^ . "RIV/00216208:11120/09:00002078!RIV10-MZ0-11120___" . . "148" . "RIV/00216208:11120/09:00002078" . "3"^^ . . "Arenbergerov\u00E1, Monika" . . "malignant melanoma; incidence; dermoscopy; circulating cells; sentinel lymph node; immunotherapy; chemotherapy; follow up"@en . "Malignant melanoma: standards and innovation in diagnostics and therapy"@en . "Malignant melanoma: standards and innovation in diagnostics and therapy"@en . . "Arenberger, Petr" . . . . . . "11120" . "Malign\u00ED melanom: standardy a inovace v diagnostice a terapii"@cs . "Malign\u00ED melanom k\u016F\u017Ee vznik\u00E1 neoplastickou proliferac\u00ED melanocyt\u016F. Tendence k \u010Dasn\u00E9mu lymfogenn\u00EDmu a hematogenn\u00EDmu metast\u00E1zov\u00E1n\u00ED \u0159ad\u00ED melanom k vysoce zhoubn\u00FDm n\u00E1dor\u016Fm. Onemocn\u011Bn\u00ED se objevuje pom\u011Brn\u011B brzy, a tak je \u010Dtvrtina pacient\u016F s melanomem mlad\u0161\u00ED 40 let a pr\u016Fm\u011Brn\u00FD v\u011Bk melanomov\u00E9ho pacienta je 54 let. Incidence tohoto tumoru konstantn\u011B stoup\u00E1, ro\u010Dn\u011B zhruba o 5%. Ve st\u0159edn\u00ED Evrop\u011B se v sou\u010Dasnosti pohybuje incidence kolem 14 p\u0159\u00EDpad\u016F na 100 000 obyvatel za rok, v USA mezi 10-25 a nejvy\u0161\u0161\u00ED incidence 50-60 nov\u00FDch p\u0159\u00EDpad\u016F je zaznamen\u00E1v\u00E1na v Austr\u00E1lii. Progn\u00F3za pacienta je v\u00FDznamn\u011B z\u00E1visl\u00E1 na tlou\u0161\u0165ce tumoru, proto je v\u010Dasn\u00E1 diagnostika nezbytn\u00FDm p\u0159edpokladem p\u0159\u00EDzniv\u00E9ho pr\u016Fb\u011Bhu onemocn\u011Bn\u00ED. Zv\u00FD\u0161en\u00ED p\u0159esnosti klinick\u00E9 diagn\u00F3zy melanomu p\u0159inesla dermatoskopie, p\u0159edev\u0161\u00EDm pak ve sv\u00E9 digit\u00E1ln\u00ED podob\u011B, kter\u00E1 zlep\u0161\u00ED \u0161kolen\u00E9mu dermatologovi p\u0159esnost klinick\u00E9 diagn\u00F3zy ze 70 na v\u00EDce ne\u017E 95%. Mortalita na malign\u00ED melanom z\u016Fst\u00E1v\u00E1 od osmdes\u00E1t\u00FDch let 20. stolet\u00ED konstantn\u00ED, a proto je velk\u00FD tlak na objeven\u00ED nov\u00FDch l\u00E1te" .